USE OF INSTENON IN THE TREATMENT OF THE BRONCHIAL OBSTRUCTIVE
SYNDROME IN YOUNG CHILDREN
Akhmedova
D.I., Ashurova D.T.
The First State Medical Institute, The
Republican Research Centre of Emergency Medical Care, Tashkent, Uzbekistan
The
importance of the studying of the bronchial obstructive syndrome in the
young children is associated with its growing rate, frequent recurrences,
complex therapy and frequent refractory to the treatment. The retrospective
analysis showed that in 32,4% of children with syndrome of bronchial
obstruction the perinatal encephalopathy was found. The hard course of the
syndrome with its recurrences was noted in 37,2% of children with perinatal
encephalopathy. In this connection for increasing efficacy of the bronchial
obstruction it is also necessary to improve brain metabolism. With this
purpose we used instenon, which included three components (gexobendin,
etamivan, etophyamin). Additionally to the improvement of the cerebral
circulation this drug has also bronchial dilatating potentiality. Clinical
observation and immunological investigations in 35 infants of the first
year of life with syndrome of bronchial obstruction who received complex
therapy including instenon showed favourable effect of this agent on the
outcome of treatment and prognosis of disease. This, in the majority of
children (84%) this syndrome stopped during 203 days, recurrences were
absent The positive dynamics was noted in relation to immunologic
indicators which had reliable differences from indicators in children who
did not receive instenon, that is, CD3- 61,3+_2,1%; CD4-32,1+_1,8%; CD8-
19.0+_0.9%; CD16-13,5%+_1.3; CD22-8,0+_1,1: ACL cor-2,2+_0,8 ACL pulm -
2,5+_0,6% (before treatment these indicators were, respectively: 52,0+_2,1;
44,5+_1.7; 17,2+_1,5; 16,3+_2,1; 14,2+_1,4; 4,1+_0,16; 5,1+_0,13). On the basis of this results
Instenon may be recommended for treatment of the syndrome of bronchial
obstruction.